- Home
- FTS vs NTRA Comparison
FTS vs NTRA Comparison
Compare FTS & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTS
- NTRA
- Stock Information
- Founded
- FTS 1885
- NTRA 2003
- Country
- FTS Canada
- NTRA United States
- Employees
- FTS N/A
- NTRA N/A
- Industry
- FTS Electric Utilities: Central
- NTRA Medical Specialities
- Sector
- FTS Utilities
- NTRA Health Care
- Exchange
- FTS Nasdaq
- NTRA Nasdaq
- Market Cap
- FTS 24.4B
- NTRA 21.5B
- IPO Year
- FTS N/A
- NTRA 2015
- Fundamental
- Price
- FTS $47.41
- NTRA $161.76
- Analyst Decision
- FTS Hold
- NTRA Strong Buy
- Analyst Count
- FTS 1
- NTRA 16
- Target Price
- FTS $72.00
- NTRA $185.56
- AVG Volume (30 Days)
- FTS 512.9K
- NTRA 1.3M
- Earning Date
- FTS 07-30-2025
- NTRA 08-07-2025
- Dividend Yield
- FTS 3.67%
- NTRA N/A
- EPS Growth
- FTS 5.83
- NTRA N/A
- EPS
- FTS 2.30
- NTRA N/A
- Revenue
- FTS $8,159,460,114.00
- NTRA $1,831,000,000.00
- Revenue This Year
- FTS $10.96
- NTRA $19.92
- Revenue Next Year
- FTS $4.24
- NTRA $16.02
- P/E Ratio
- FTS $20.70
- NTRA N/A
- Revenue Growth
- FTS 3.64
- NTRA 51.50
- 52 Week Low
- FTS $38.96
- NTRA $92.14
- 52 Week High
- FTS $50.06
- NTRA $183.00
- Technical
- Relative Strength Index (RSI)
- FTS 48.73
- NTRA 48.01
- Support Level
- FTS $46.79
- NTRA $158.00
- Resistance Level
- FTS $48.07
- NTRA $170.48
- Average True Range (ATR)
- FTS 0.57
- NTRA 5.35
- MACD
- FTS 0.00
- NTRA -1.27
- Stochastic Oscillator
- FTS 40.98
- NTRA 29.39
About FTS Fortis Inc.
Fortis owns and operates eight utility transmission and distribution subsidiaries in Canada and the United States, serving more than 3.4 million electricity and gas customers. The company has smaller stakes in electricity generation and several Caribbean utilities. Subsidiary ITC operates electric transmission in seven US states, with more than 16,000 miles of high-voltage transmission lines in operation.
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.